Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 34,355 $ 18,941
Marketable securities-available for sale, at fair value 7,180
Prepaid expenses and other 1,130 1,019
Total current assets 35,485 27,140
Property and equipment, net 118 150
Restricted cash 89 89
Intangible asset 120 120
Security deposits 11 11
Total assets 35,823 27,510
Current liabilities:    
Accounts payable 1,179 872
Accrued expenses 651 1,244
Total current liabilities 1,830 2,116
Deferred rent payable 24 33
Total liabilities 1,854 2,149
Commitments (See Note 8)
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 150,000,000 and 15,000,000 shares authorized; 7,490,151 and 3,918,147 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively, 17,760 and 2,496 shares to be issued as of June 30, 2017 and December 31, 2016, respectively 7 4
Additional paid in capital 185,055 166,604
Accumulated deficit (151,084) (141,240)
Accumulated other comprehensive loss (9) (7)
Total stockholders' equity 33,969 25,361
Total liabilities and stockholders' equity $ 35,823 $ 27,510
v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
COSTS AND EXPENSES:        
Research and development $ 2,806 $ 7,516 $ 5,800 $ 18,187
General and administrative 2,016 2,320 4,113 5,663
Total costs and expenses 4,822 9,836 9,913 23,850
Operating loss (4,822) (9,836) (9,913) (23,850)
Interest income, net 42 30 69 68
NET LOSS $ (4,780) $ (9,806) $ (9,844) $ (23,782)
Net loss per common share, basic and diluted (in dollars per share) $ (0.65) $ (4.97) $ (1.74) $ (12.31)
Weighted average common shares outstanding, basic and diluted (in shares) 7,327,890 1,973,643 5,666,457 1,931,193
v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (9,844) $ (23,782)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of premium on marketable securities 6 46
Depreciation of property and equipment 34 67
Stock-based compensation 1,044 1,623
Changes in operating assets and liabilities:    
Prepaid expenses (111) 930
Accounts payable 307 (1,117)
Accrued expenses and deferred rent (590) (1,247)
Net cash used in operating activities (9,154) (23,480)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (2) (66)
Maturities of marketable securities 7,174 7,518
Net cash provided by investing activities 7,172 7,452
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 14
Proceeds, net of expenses of $1,168 and $1,065, from sale of common stock 17,386 11,783
Net cash provided by financing activities 17,400 11,783
Effect of currency rate change on cash (4) 8
Net increase (decrease) in cash and cash equivalents 15,414 (4,237)
Cash and cash equivalents, beginning of the period 18,941 19,175
Cash and cash equivalents, end of period 34,355 14,938
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 10 $ 113